As part of the agreement, Sanofi will provide Alloy with upfront license fees and near-term preclinical milestone payments up ...

Sanofi has paid the upfront fee and committed to discovery, development and commercial milestones of over $400 million to get ...

Alloy Therapeutics Inc. ("Alloy"), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Privately-held US biotech Alloy Therapeutics has announced a target specific collaboration and license agreement for the use ...

Sanofi has enlisted drug discovery company Alloy Therapeutics to develop an antisense oligonucleotide drug for a single, ...

A U.S. government agency warned Sanofi that it faces sanctions over plans to change the way payments are made to most hospitals participating in a drug discount program, the second time in recent ...

Sanofi has leapt in to buy Ablynx for €3.9 billion ($4.85bn) outbidding an offer from Novo Nordisk which the European biotech had declined two weeks ago. For Sanofi, the acquisition comes hot on ...

Sanofi, a leader in immunology, had said it will invest $1.5 billion in the development of Teva's anti-TL1A drug undergoing phase 2 trials. U.S.-listed shares of Teva and Sanofi rose 19% and 4% ...

This is the 30th annual Adopt-a-Family event put on by employees at Sanofi Pasteur, a pharmaceutical company in Swiftwater. This year, the employees adopted 50 families and went shopping ...

Analyst Graham Parry from Bank of America Securities maintained a Buy rating on Sanofi (SNYNF – Research Report) and keeping the price target at €122.00. Discover top-rated stocks from highly ...

Sanofi SNY shares soared 6.7% in the last trading session to close at $48.94. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the ...

JERUSALEM, Dec 17 (Reuters) - (This Dec.17 story has been corrected to say the results were for ulcerative colitis, not for both the diseases, in paragraph 5) Teva and Sanofi said last year they ...